An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)

Phase 3TerminatedNCT00449111

Organon and Co11 enrolled

Overview

Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypertension

Interventions

MK0954, losartan potassium / Duration of Treatment - 12 weeksDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1 * Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1 Exclusion Criteria: * History of angina pectoris that has not been stabilized in the past 6 weeks * History of clinically significant abnormal lab results or diseases * Myocardial infarction within the past 6 months * Stroke in the past 6 months

Outcomes

Primary Outcomes

Change of diastolic blood pressure after 6 weeks of treatment with cozaar plus

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.